Table 3.
Summary of best overall response per RECIST v1.0
| All patients (N = 50)a | |
|---|---|
| Best overall response, n (%) | |
| Complete response (CR) | 1 (2) |
| Partial response (PR) | 4 (8) |
| Stable disease (SD) | 20 (40) |
| SD ≥ 24 weeks | 2 (4) |
| Progressive disease | 20 (40) |
| Unknown | 5 (10) |
| Objective response rate (ORR; CR + PR), n (%) [90% CI]b | 5 (10) [4.0–19.9] |
| Disease control rate (DCR; CR + PR + SD), n (%) [90% CI] | 25 (50) [37.6–62.4] |
| Clinical benefit rate (CBR; CR + PR + SD ≥ 24 weeks), n (%) [90% CI] | 7 (14) [6.8–24.7] |
a
Three patients received a loading dose of trastuzumab but not buparlisib, and are not included here
b
90% CIs for ORR, DCR and CBR were obtained using the exact binomial 90% CI test